BioCentury
ARTICLE | Management Tracks

Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem   

February 2, 2021 2:24 AM UTC

Gene editing play CRISPR Therapeutics AG (NASDAQ:CRSP) hired Philippe Drouet as chief commercial officer. He was SVP, global oncology marketing & market access at Merck & Co. Inc. (NYSE:MRK), where he launched and commercialized Keytruda pembrolizumab.

Neurology company Cerevance Inc. hired Carrie Ann Cook as CBO. Cook served as VP of business development at Canbridge Pharmaceuticals Inc. and before that held leadership roles Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), Merck KGaA (Xetra:MRK), Novartis AG (NYSE:NVS; SIX:NOVN) and Baxter Healthcare Corp...